Tisento Therapeutics
Nexo Therapeutics is a small molecule oncology company dedicated to the discovery and development of new drugs for cancer patients who currently lack meaningful therapies. Nexo combines covalent ligand discovery and chemical biology with expertise in cancer biology and medicinal chemistry to target fundamental drivers of cancer by innovative approaches. With facilities in Golden, CO and Watertown, MA, Nexo is led by Founder and CEO, Andrew Phillips, PhD. For more information, please visit www.nexotx.com.
Tisento Therapeutics
Nexo Therapeutics is a biotechnology company focused on discovering and developing novel cancer therapies against previously intractable targets.
About
Needs Assessment
Active buying signals and potential business opportunities
Technology Requirements
Ligand discovery platform
Chemical biology platform
High-throughput screening technologies
Proteomics analysis tools
Service Requirements
Drug discovery services
Drug development services
Consulting on pharmacology and toxicology
Training on platform usage
Infrastructure Requirements
Research labs
High-performance computing resources
Secure data storage
Scalable proteomics infrastructure
Talent Requirements
Experts in covalent ligand discovery
Chemical biologists
Pharmacologists
Protein engineers
AI Insights
Growth Trajectory
With $60 million in Series A funding and a partnership with MD Anderson, Nexo Therapeutics demonstrates strong growth potential in the development of novel cancer therapies.
Market Opportunity
Nexo Therapeutics has a significant market opportunity by focusing on intractable cancer targets and leveraging its unique drug discovery platform to address unmet medical needs.
Access Our Live VC Funding Database
30,000+ funded startups
tracked in the last 3 months
B2B verified emails
of key decision makers
Growth metrics
Real-time company performance data
Live updates
of new VC funding rounds
Advanced filters
for sophisticated queries
API access
with multiple export formats